Skip to Content

Zioptan Approval History

  • FDA approved: Yes (First approved February 10th, 2012)
  • Brand name: Zioptan
  • Generic name: tafluprost
  • Dosage form: Ophthalmic Solution
  • Company: Merck & Co., Inc.
  • Treatment for: Glaucoma, Open Angle, Intraocular Hypertension

Zioptan (tafluprost ophthalmic solution) is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Development History and FDA Approval Process for Zioptan

Feb 13, 2012Approval FDA Approves Zioptan (tafluprost ophthalmic solution), Merck's Once-Daily, Preservative-Free Ophthalmic Medication
Mar  9, 2011Merck Announces FDA Acceptance of New Drug Application for Investigational Ophthalmic Medication Saflutan (tafluprost)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.